ResearcherThe Cancer Institute HospitalActive in the last 2 years
Yoshihiro Ono
Matched on OpenAlex author ID A5100828880. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 29
2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers
Papers 7
- Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal comparative study. Co-author DOI 10.1093/bjsopen/zraf026↗
- Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-17407-5↗
- ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-025-17458-8↗
- Unique Biology of Pancreatic Ductal Adenocarcinoma Accompanied by Rapidly Impaired Diabetes: A Favorable Long-Term Survival Following Curative Resection. First author DOI 10.1245/s10434-023-14408-0↗
- New approach of circumferential lymph node dissection around the superior mesenteric artery for pancreatic cancer during pancreaticoduodenectomy (with video). Co-author DOI 10.1007/s00423-023-03159-x↗
- Impact of sarcopenia on S1 adjuvant chemotherapy and prognosis in pancreatic cancer patients. Co-author DOI 10.5582/bst.2023.01209↗
- KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Co-author DOI 10.1111/cas.15398↗
Closest collaborators
The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yosuke Inoue · 7 shared papers, 2022–2025 · strength 1.36
- Paper ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicato… DOI 10.1245/s10434-025-17458-8↗
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Atsushi Oba · 6 shared papers, 2023–2025 · strength 1.25
- Paper ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicato… DOI 10.1245/s10434-025-17458-8↗
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Hiromichi Ito · 6 shared papers, 2023–2025 · strength 1.25
- Paper ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicato… DOI 10.1245/s10434-025-17458-8↗
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Yu Takahashi · 5 shared papers, 2022–2025 · strength 0.89
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Paper Unique Biology of Pancreatic Ductal Adenocarcinoma Accompanied by Rapidly Impaired Diabetes: A Favorable Long-Term Surv… DOI 10.1245/s10434-023-14408-0↗
- Paper New approach of circumferential lymph node dissection around the superior mesenteric artery for pancreatic cancer durin… DOI 10.1007/s00423-023-03159-x↗
- Aya Maekawa · 3 shared papers, 2025 · strength 0.68
- Paper ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicato… DOI 10.1245/s10434-025-17458-8↗
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Takafumi Mie · 3 shared papers, 2025 · strength 0.68
- Paper ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicato… DOI 10.1245/s10434-025-17458-8↗
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Kojiro Omiya · 3 shared papers, 2025 · strength 0.68
- Paper ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicato… DOI 10.1245/s10434-025-17458-8↗
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Naoki Sasahira · 3 shared papers, 2022–2025 · strength 0.54
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Paper KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. DOI 10.1111/cas.15398↗
- Manabu Takamatsu · 3 shared papers, 2022–2024 · strength 0.50
- Paper Unique Biology of Pancreatic Ductal Adenocarcinoma Accompanied by Rapidly Impaired Diabetes: A Favorable Long-Term Surv… DOI 10.1245/s10434-023-14408-0↗
- Paper New approach of circumferential lymph node dissection around the superior mesenteric artery for pancreatic cancer durin… DOI 10.1007/s00423-023-03159-x↗
- Paper KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. DOI 10.1111/cas.15398↗
- Yu Takahashi · 2 shared papers, 2025 · strength 0.47
- Paper ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicato… DOI 10.1245/s10434-025-17458-8↗
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Masato Ozaka · 2 shared papers, 2025 · strength 0.43
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Akio Saiura · 2 shared papers, 2023–2024 · strength 0.39
- Tomotaka Kato · 2 shared papers, 2022–2023 · strength 0.30
- Paper New approach of circumferential lymph node dissection around the superior mesenteric artery for pancreatic cancer durin… DOI 10.1007/s00423-023-03159-x↗
- Paper KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. DOI 10.1111/cas.15398↗
- Yuki Hirose · 1 shared paper, 2025 · strength 0.21
- Toshifumi Wakai · 1 shared paper, 2025 · strength 0.21
- Sho Kiritani · 1 shared paper, 2024 · strength 0.20
- Kumi Takagi · 1 shared paper, 2023 · strength 0.18
- Kiyoshi Hasegawa · 1 shared paper, 2022 · strength 0.11
- Tsuyoshi Takeda · 1 shared paper, 2022 · strength 0.11
- Tatsunori Suzuki · 1 shared paper, 2022 · strength 0.11
- Tsuyoshi Hamada · 1 shared paper, 2022 · strength 0.11
- Minoru Kitago · 1 shared paper, 2022 · strength 0.11
- Yohei Masugi · 1 shared paper, 2022 · strength 0.11
- Yutaka Nakano · 1 shared paper, 2022 · strength 0.11
- Michiie Sakamoto · 1 shared paper, 2022 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.